IL22 and infection: Despite persistent C. rodentium-associated pathology and higher faecal burden in the early and peak infection phases (Fig. 4A), FT-treated Il22−/− mice cleared C. rodentium at rates comparable to Il22+/+ mice (Fig. 7A) and progressively recovered from colonic damage.